$SUPN News

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript

Supernus Pharmaceuticals (NASDAQ:SUPN) Beats Q1 Estimates as Growth Products Drive 39% Revenue Surge

Supernus Pharmaceuticals Q1 2026 Earnings Call Transcript

Supernus Pharmaceuticals Affirms FY2026 Sales Guidance of $840.000M-$870.000M vs $862.242M Est

Supernus Pharmaceuticals Q1 EPS $(0.04) Misses $(0.01) Estimate, Sales $207.705M Beat $192.918M Estimate

Supernus Pharmaceuticals Enters Asset Purchase Agreement With Navitor On April 1, 2026; To Buy Assets Related To NV-5138 Or SPN-820, Including IP And Inventory; Purchase Price Includes Phase 2b Study And Milestone Payments Up To $350M; Agreement Includes Five-year Non-Compete And Non-Solicitation Covenant

Supernus Pharma Insider Sells $5.4 Million as Stock Surges 53% in a Year

3 Reasons SUPN is Risky and 1 Stock to Buy Instead

Supernus Pharmaceuticals, Inc. (SUPN) Presents at Barclays 28th Annual Global Healthcare Conference Transcript

Is It Too Late To Consider Supernus Pharmaceuticals (SUPN) After A 74% One Year Rally?

Supernus Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

Supernus Pharmaceuticals shares are trading higher after the company reported better-than-expected Q4 financial results.

Supernus Pharmaceuticals Q4 Earnings Call Highlights

Supernus Pharmaceuticals Inc (SUPN) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...

Supernus Pharmaceuticals, Inc. (SUPN) Q4 2025 Earnings Call Transcript

Supernus (SUPN) Reports Q4 Earnings: What Key Metrics Have to Say

Supernus Pharmaceuticals Inc (NASDAQ:SUPN) Posts Strong Q4 Beat as CNS Portfolio Accelerates Growth

Supernus: Q4 Earnings Snapshot

Supernus Pharmaceuticals’s (NASDAQ:SUPN) Q4 CY2025: Strong Sales